However, they further concluded that Src inhibition combined with inhibition of one or more alternative pathways that are also implicated in the metastatic behavior of osteosarcoma (ezrin, insulin-like growth factor-I receptor pathway, and CXCR4) might be a rational approach for future clinical trials [33]. Here, SRC is linked to osteosarcoma.